English
Deutsch
Français
Italiano
EspañolCorrecting the Record: Exposing False Information In News Reports, Articles, and Correspondences
Numerous inaccuracies and misleading statements have been communicated in the popular press, published articles, and correspondences about COLCRYS®, unapproved colchicine, and URL Pharma’s extensive clinical program to improve the safety of colchicine. These inaccuracies are exposed here and corrected.
-
New England Journal of Medicine
- The New England Journal of Medicine (NEJM) published a Perspective on April 14, 2010 that contained numerous inaccuracies and misleading assertions about COLCRYS® and our substantial efforts to bring patients and physicians a better and safer colchicine. We have reprinted the article and interposed our responses to correct the false or misleading statements.
-
Wall Street Journal
- On April 12, 2010, the Wall Street Journal published an article on colchicine and COLCRYS® that contained some correct information but also communicated a number of inaccuracies. We have reprinted the article and interposed our responses to correct and clarify these inaccuracies.
-
American College of Rheumatology
- There was an unfortunate series of letters involving the ACR – among them are communications from the American College of Rheumatology (ACR) to FDA and between ACR and URL Pharma. Finally, there is a statement of facts from FDA regarding Colcrys and unapproved colchicine. We regret the need to publish these letters in sequence here but we feel compelled to do so to correct the record for those who are interested in investigating this matter further. A complete reading of this set of letters is quite enlightening.
- Letter from ACR to FDA dated December 18, 2009
- Letter from CEO of URL Pharma to ACR dated February 16, 2010
- Letter from ACR to URL Pharma dated March 24, 2010
- Letter from URL Pharma to ACR dated March 29, 2010
- FDA Statement of Position Letter on Unapproved Colchicine dated March 3, 2010 from the FDA Center for Drug Evaluation and Research
- There was an unfortunate series of letters involving the ACR – among them are communications from the American College of Rheumatology (ACR) to FDA and between ACR and URL Pharma. Finally, there is a statement of facts from FDA regarding Colcrys and unapproved colchicine. We regret the need to publish these letters in sequence here but we feel compelled to do so to correct the record for those who are interested in investigating this matter further. A complete reading of this set of letters is quite enlightening.
-
Arthritis Today
- On April 20, 2010, Arthritis Today published an article that unfortunately contained some inaccuracies. We have reprinted that article with our corrections to the inaccurate statements placed where appropriate to give the reader accurate information.
-
Myths and Facts
- We address some of the most commonly repeated inaccurate or misleading statements about COLCRYS®, followed by the key facts that refute each of these myths.